{"id":730063,"date":"2023-02-09T07:13:46","date_gmt":"2023-02-09T12:13:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-09T07:13:46","modified_gmt":"2023-02-09T12:13:46","slug":"lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/","title":{"rendered":"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference"},"content":{"rendered":"
\n

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V.<\/a>\u00a0(Nasdaq: LVTX<\/a>), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference.<\/p>\n

\n Presentation Details<\/u>
\n
Format: Presentation
Date: Thursday, February 16, 2023
Time: 1:00 p.m.-1:30 p.m. EST<\/p>\n

A webcast of the presentation can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at: https:\/\/ir.lavatherapeutics.com\/news-events\/events<\/a>. A replay will be archived for 90 days following the presentation date.<\/p>\n

\n About LAVA Therapeutics<\/strong>
\n
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody\u2122 platform<\/a> to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V\u03b39V\u03b42 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company\u2019s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1\/2a clinical study (NCT04887259). A Phase 1\/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000<\/a>). For more information, please visit\u00a0www.lavatherapeutics.com<\/a>, and follow us on\u00a0LinkedIn<\/a>,\u00a0Twitter<\/a>\u00a0and\u00a0YouTube<\/a>.<\/p>\n

\n
\n CONTACTS<\/u>
\n <\/strong>
\n
Investor Relations
ir@lavatherapeutics.com<\/a><\/p>\n

Argot Partners (IR\/Media)
212-600-1902
lava@argotpartners.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V.\u00a0(Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference. Presentation Details Format: Presentation Date: Thursday, February 16, 2023Time: 1:00 p.m.-1:30 p.m. EST A webcast of the presentation can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at: https:\/\/ir.lavatherapeutics.com\/news-events\/events. A replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage … <\/p>\n

Continue reading “LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-730063","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V.\u00a0(Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference. Presentation Details Format: Presentation Date: Thursday, February 16, 2023Time: 1:00 p.m.-1:30 p.m. EST A webcast of the presentation can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at: https:\/\/ir.lavatherapeutics.com\/news-events\/events. A replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage … Continue reading "LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T12:13:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-02-09T12:13:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/\",\"name\":\"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=\",\"datePublished\":\"2023-02-09T12:13:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Market Newsdesk","og_description":"UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V.\u00a0(Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference. Presentation Details Format: Presentation Date: Thursday, February 16, 2023Time: 1:00 p.m.-1:30 p.m. EST A webcast of the presentation can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at: https:\/\/ir.lavatherapeutics.com\/news-events\/events. A replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage … Continue reading \"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-09T12:13:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference","datePublished":"2023-02-09T12:13:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/","name":"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=","datePublished":"2023-02-09T12:13:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTQ1NSM1Mzk5MDM4IzIyMDY3OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-at-the-2023-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=730063"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730063\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=730063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=730063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=730063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}